Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …

The MYC transcription factor, encoded by the c‐MYC proto‐oncogene, is activated by
growth‐promoting signals, and is a key regulator of biosynthetic and metabolic pathways …

Cancer is a neoplastic disease that remains a global challenge with a reported prevalence
that is increasing annually. Though existing drugs can be applied as single or combined …

Gene editing-based therapeutic strategies grant the power to override cell machinery and
alter faulty genes contributing to disease development like cancer. Nowadays, the principal …

The technology known asPROTACs (PROteolysisTArgeting Chimeras) is a method of
protein degradation. Utilising bifunctional small molecules, the ubiquitin-proteosome system …

Rapid advances in genomics have opened unprecedented possibilities to explore the
mutational landscapes in malignant diseases, such as B-cell acute lymphoblastic leukemia …

Polyploid cells demonstrate biological plasticity and stress adaptation in evolution;
development; and pathologies, including cardiovascular diseases, neurodegeneration, and …

Prostate cancer (PCa) is a malignant tumor that seriously threatens men's health worldwide.
Recently, stromal cells in the tumor microenvironment (TME) have been reported to …

The underlying cause of cancer is genetic disruption, so gene editing technologies,
particularly CRISPR/Cas systems can be used to go against cancer. The field of gene …

The MYC proto‐oncogene and BRD4, a BET family protein, are two cardinal proteins that
have a broad influence in cell biology and disease. Both proteins are expressed …